Volume | 116,078 |
|
|||||
News | - | ||||||
Day High | 39.67 | Low High |
|||||
Day Low | 38.42 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
38.91 | 38.42 | 39.67 | 38.85 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,009 | 116,078 | $ 39.13 | $ 4,542,176 | - | 22.11 - 53.18 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:44:01 | 1 | $ 38.5252 | USD |
Celldex Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.17B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Celldex Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 39.03 | 40.45 | 36.78 | 38.81 | 679,821 | -0.505 | -1.29% |
1 Month | 41.64 | 42.38 | 36.78 | 40.02 | 627,272 | -3.12 | -7.48% |
3 Months | 36.24 | 53.18 | 34.65 | 43.29 | 964,123 | 2.29 | 6.31% |
6 Months | 26.00 | 53.18 | 22.11 | 37.75 | 886,187 | 12.53 | 48.17% |
1 Year | 36.51 | 53.18 | 22.11 | 35.64 | 672,617 | 2.02 | 5.52% |
3 Years | 26.85 | 57.20 | 19.85 | 35.71 | 626,956 | 11.68 | 43.48% |
5 Years | 3.66 | 57.20 | 1.50 | 24.45 | 682,146 | 34.87 | 952.60% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |